Is Source Natural overvalued or undervalued?

As of 13 November 2025, the valuation grade for Source Natural has moved from attractive to fair, indicating a reassessment of its market position. The company is currently fairly valued based on its financial metrics, with a PE ratio of 29.30, an EV to EBITDA of 16.59, and a PEG ratio of 0.46. These ratios suggest that while the company has growth potential, its current valuation aligns with its earnings and growth prospects.
In comparison to its peers, Source Natural's valuation appears reasonable. For instance, Sun Pharma has a significantly higher PE ratio of 36.15, while Cipla, considered attractive, has a PE of 22.65. The notable outperformance of Source Natural's PEG ratio at 0.46 compared to peers like Divi's Lab, which has a PEG of 1.99, further supports the conclusion that Source Natural is fairly valued. Additionally, the company's stock has underperformed against the Sensex over the past year, with a decline of 41.67% compared to the Sensex's gain of 8.74%, reinforcing the notion that the stock may not be undervalued at this time.